Valuation : PREDILIFE

Market Cap 44.2L 51.29L 41.44L 37.83L 71.26L 49Cr 71.49L 4.92Cr 1.92Cr 25Cr 1.93Cr 1.88Cr 82Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 91.97L 1.07Cr 86.24L 78.72L 1.48Cr 102.01Cr 1.49Cr 10Cr 3.99Cr 51Cr 4.01Cr 3.92Cr 170.75Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 week+0.90%
Current month-6.67%
1 month-6.67%
3 months-61.25%
6 months-64.22%
Current year-62.79%
1 week 1.11
Extreme 1.11
1.12
1 month 1.11
Extreme 1.11
1.5
Current year 0.9
Extreme 0.9
4
1 year 0.9
Extreme 0.9
4
3 years 0.9
Extreme 0.9
24
5 years 0.9
Extreme 0.9
24
10 years 0.9
Extreme 0.9
24
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Director/Board Member 46 01/01/2018
Chairman 56 01/01/2004
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
27/07/23 Buy

Chief Executive Officer

1,200 0.0328%
23/03/22 Sell

Chief Executive Officer

3,000 0.0820%
09/03/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+0.90%-65.54%-80.00% 51.29L
-4.73%-3.08%+91.12%+277.10% 402.02Cr
-3.03%-3.38%+259.19%+30.88% 362.83Cr
-4.22%+2.43%+42.85%+64.79% 348.41Cr
-4.91%+2.43%+264.49%+442.37% 257.58Cr
-3.09%-6.35%-26.54%-26.21% 225.47Cr
+6.10%+7.10%+39.80% - 158.91Cr
+11.76%+16.89%+37.38%+60.22% 117.84Cr
-8.24%-11.11%+217.36%-26.30% 114.42Cr
-2.87%+25.09%+27.90%+184.74% 68Cr
Average -1.32%-0.03%+88.80%+103.07% 205.55Cr
Weighted average by Cap. -2.54%-0.51%+119.29%+142.22%

Financials

2024 2025
Net sales 5L 6L 5L 4L 8L 5.47Cr 8L 54.86L 21.41L 2.76Cr 21.49L 21.02L 9.16Cr 8L 10L 8L 7L 13.48L 9.27Cr 13.52L 92.97L 36.28L 4.68Cr 36.42L 35.62L 16Cr
Net income -42.65L -49.49L -39.99L -36.5L -68.76L -47Cr -68.98L -4.74Cr -1.85Cr -24Cr -1.86Cr -1.82Cr -79Cr -39.34L -45.66L -36.89L -33.67L -63.44L -44Cr -63.64L -4.38Cr -1.71Cr -22Cr -1.71Cr -1.68Cr -73Cr
Net Debt 35.38L 41.06L 33.18L 30.28L 57.05L 39Cr 57.23L 3.94Cr 1.54Cr 20Cr 1.54Cr 1.51Cr 66Cr 47.78L 55.44L 44.8L 40.89L 77.03L 53Cr 77.28L 5.31Cr 2.07Cr 27Cr 2.08Cr 2.04Cr 89Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
28/26/28 €1.120 0.00% 0
27/26/27 €1.120 +0.90% 100
26/26/26 €1.110 0.00% 0
25/26/25 €1.110 0.00% 22
24/26/24 €1.110 0.00% 100

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock